胶质瘤化疗临床实验简介汇总

杀杀

汇总胶质瘤化疗药相关的II-III期临床实验以及大致简介

Temozolomide(TMZ

A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) PMID:27686946
III期临床试验,对比单独放疗/单独TMZ的高风险II级胶质瘤患者的生存情况(对IDH进行分类

Radiation Therapy Oncology Group 0424-RTOG0424 PMID:25680596
II期临床试验,比较了单独放射治疗和同时进行放射治疗+TMZ的患者生存率

CODEL (North Central Cancer Treatment Group [NCCTG]/Alliance for Clinical Trials in Oncology N0577; European Organisation for Research and Treatment Center [EORTC] 26081-22086; NRG 1071; Canadian Cancer Trials Group [CCTG] CEC.6) PMID: 32678879
比较RT, RT + TMZ, TMZ 对新诊断的 1p/19q 共缺失的少突胶质细胞瘤的疗效

AINO (Italian Association for Neuro-Oncology) study PMID: 31556015
TMZ在高风险少突胶质瘤的不同分子分型中的作用

Procarbazine, CCNU, and Vincristine(PCV三药联用

NRG Oncology/RTOG 9802 PMID:27050206
III期临床实验,比较高风险II级胶质瘤中RT治疗与RT+PCV治疗的生存差异

EORTC brain tumor group study 26951 PMID: 23071237
III期临床实验,比较间变性少突胶质瘤中RT治疗与RT+PCV治疗的生存差异

NRG Oncology/RTOG 9402 PMID: 23071247
III期临床实验,比较AO/AOA中RT治疗与RT+PCV治疗的生存差异

你可能感兴趣的:(胶质瘤化疗临床实验简介汇总)